FOSTER CITY, CA -- (Marketwired) -- 03/12/14 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the fourth quarter and year ended December 31, 2013.
ZADAXIN® revenues were $96.3 million for the full year 2013, a $15.9 million or 14% decrease, compared to $112.2 million for 2012. SciClone believes its ZADAXIN product revenues in the first half of 2013, and the fourth quarter of 2012, were adversely affected by the increase in channel inventory it experienced in the latter half of 2012. SciClone believes channel inventory for ZADAXIN has returned to normalized levels. ZADAXIN sales were $30.5 million in the fourth quarter of 2013, an increase of $9.7 million or 47%, compared to $20.8 million in the same period in 2012.
SciClone's full year 2013 and fourth quarter promotion services revenues were negatively affected by the non-renewal of and associated wind-down of services for the promotion agreement with Sanofi Aventis S.A. ("Sanofi") at the end of its term on December 31, 2013. SciClone and Sanofi are currently in a dispute concerning Sanofi's performance obligations under the agreement which resulted in SciClone's decision to defer revenue recognition of Sanofi promotion fees in the fourth quarter of 2013, pending resolution of the dispute.
On a GAAP basis, SciClone reported net income of $11.0 million or $0.20 per share on both a basic and diluted basis for the full year 2013, compared to net income of $9.6 million or $0.17 and $0.16 per share on a basic and diluted basis, respectively, for the full year 2012. Net income for the fourth quarter of 2013 was approximately $36,000, compared to net income of $1.9 million for the same period of last year, or $0.00 per share on both a basic and diluted basis, compared with $0.03 per share on both a basic and diluted basis for the same period of last year.
SciClone's non-GAAP net income for the full year 2013 was $23.2 million or $0.43 and $0.42 per share on a basic and diluted basis, respectively, compared to $37.8 million or $0.67 and $0.65 per share on a basic and diluted basis, respectively, for the same period of last year. SciClone reported non-GAAP net income for the fourth quarter of 2013 of $4.0 million, compared to $2.0 million for the same period of last year, or $0.08 and $0.07 per share on a basic and diluted basis, respectively, for the fourth quarter of 2013, compared to $0.04 per share on both a basic and diluted basis for the same period of last year.
"We believe that 2014 may see a return to more normal rates of growth in the China pharmaceuticals market of 15% to 20%, and that SciClone is well positioned to resume a growth trajectory this year as well," said Friedhelm Blobel, Ph.D., SciClone's Chief Executive Officer. "Having restructured our sales and marketing organization, we believe that we can more effectively focus on our high-growth opportunities, including ZADAXIN, our oncology portfolio and especially our growing cardiovascular franchise. We are implementing a suite of sophisticated and targeted sales and marketing strategies designed to increase the productivity and effectiveness of our streamlined organization. This includes an increased emphasis on academic marketing utilizing highly trained medical professionals, which should enable us to more effectively penetrate high-value hospitals and physicians in Tier 1 and 2 cities, and strengthen sales of ZADAXIN as well as our entire marketed portfolio. We anticipate continued significant growth opportunities for ZADAXIN in the indications for which it is currently approved as well as in potential new indications. For example, as the incidence and prevalence of hepatitis B expands, and there is greater evidence of growing resistance to approved antiviral therapies, we see potentially increased use of ZADAXIN as combination therapy. Similarly, we believe that in light of the publication in a peer-reviewed journal of encouraging clinical trial results, we see growing interest by physicians in using ZADAXIN as a potential adjunctive therapy to treat sepsis."
Continued Dr. Blobel: "We are hopeful that in 2014 we will see progress in moving our development portfolio forward, and, at the same time, we anticipate continued progress by our partners with our newly in-licensed cardiovascular product candidates, Neucardin® and ProFlow®. We intend to seek additional in-licensing and product promotion partnerships that can expand our marketed product portfolio and contribute to our profitability. We believe that the issues that slowed our growth in 2013 are largely behind us, and that our strengthened China management team, enhancements to our business practices and accounting controls, and strong focus on company-wide compliance will enable us to take advantage of growth opportunities, and address the challenges, in the evolving China pharma market."
Sales and marketing expenses for the full year 2013 were $55.8 million, compared with $70.3 million for the same period of last year. The decrease of $14.5 million in the 2013 period was a result of the expense-saving measures we implemented in our sales and marketing activities with the goal of achieving profitability in all of our product lines. Sales and marketing expenses for the fourth quarter of 2013 were $13.9 million, compared to $18.1 million for the same period of last year.
Research and development (R&D) expenses for the full year 2013 were $7.5 million, which included $5.0 million in upfront costs paid in 2013 related to new in-license arrangements with Zensun and Taiwan Liposome Company (TLC), compared with $5.1 million of R&D expenses for the same period of last year. R&D expenses for the fourth quarter of 2013 were $1.1 million, compared to $0.4 million for the same period of the prior year.
General and administrative (G&A) expenses for the full year 2013 were $32.5 million, compared with $21.3 million for the same period of last year. The increases were primarily attributable to higher legal and accounting costs associated with the ongoing government investigations, improvements to SciClone's Foreign Corrupt Practices Act (FCPA) compliance efforts, legal matters associated with the MEDA arbitration, and bad debt expense. For the fourth quarter of 2013, G&A expenses were $7.7 million, compared with $7.4 million for the same period of last year.
Included in reported net income of $11.0 million for the full year 2013 is net other income (expense) of $2.8 million, which is primarily comprised of $2.6 million of other income resulting from an escrow settlement. On July 8, 2013, SciClone and the representatives of the former stockholders of NovaMed entered into an escrow settlement agreement pursuant to which the Company retained approximately $0.8 million in cash and 342,300 shares of its common stock, having a combined fair value of approximately $2.6 million on the settlement date. As a result, SciClone recorded $2.6 million for the year ended December 31, 2013 in other income related to this settlement.
During the fourth quarter of 2013, SciClone recorded $1.2 million in restructuring expenses related to the planned reduction in its sales force due to the non-renewal of its distribution agreement with Sanofi in 2013. SciClone believes the restructuring will enable it to better focus resources on potential high-growth areas, including its cardiovascular franchise. Also during the fourth quarter of 2013, SciClone recorded a $2.0 million charge to reflect the Company's estimate of a probable loss incurred related to potential penalties, fines and/or other remedies in the ongoing investigations with the Securities and Exchange Commission ("SEC") and Department of Justice ("DOJ").
As of December 31, 2013, cash and cash equivalents, restricted cash and investments totaled $85.9 million, compared to $87.0 million as of December 31, 2012. SciClone has a share repurchase program under which its Board of Directors authorized $50.5 million, of which approximately $40.8 million had been utilized through December 31, 2013, and approximately $9.7 million remained available.
SciClone has presented non-GAAP information above as the Company believes this non-GAAP information is useful for investors, taken in conjunction with SciClone's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of SciClone's operating results as reported under GAAP. The non-GAAP calculations and reconciliation are provided in the accompanying table titled "Reconciliation of GAAP to Non-GAAP Net Income."
Outlook for 2014
SciClone projects its 2014 revenue to be in the range between $130 and $135 million, and its non-GAAP earnings per share to be in the range between $0.41 and $0.47. SciClone anticipates that ZADAXIN revenues in 2014 will be higher than 2013, partially offset by the loss of promotion services revenues from the non-renewal of the promotion agreement with Sanofi.
SciClone also projects that cash and investments as of December 31, 2014 will be greater than $100 million, which excludes the cash impact of any repurchases of common stock during 2014, in-licensing related payments, Zensun loan drawdown and any additional actual or probable expense, in excess of the $2 million currently reserved, for potential fines and/or other remedies related to the ongoing investigation with the Securities and Exchange Commission and Department of Justice.
Conference Call Today
SciClone is hosting a conference call today at 8:30 am ET (5:30 am PT) to provide a financial update. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.
(Replay available from March 12, 2014, at 12:30 pm ET until 11:59 pm ET on March 19, 2014)
The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of SciClone's website at www.sciclone.com. The information provided on the teleconference is accurate only at the time of the conference call, and SciClone will take no responsibility for providing updated information except as required by law.
SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Through its promotion business with pharmaceutical partners, SciClone markets multiple branded products in China which are therapeutically differentiated. The Company has successfully in-licensed products with the potential to become future market leaders and to drive the Company's long-term growth. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.
This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties relating to: the course, cost and outcome of regulatory matters, including future pricing decisions by authorities in China; the on-going regulatory investigations and expenses related thereto, including potential fines and/or other remedies; the Company's ability to execute on its goals in China and on its objectives for revenue in fiscal 2014; the dependence of its current and future revenue and prospects on third-party license, promotion or distribution agreements, including the need to renew such agreements, enter into similar agreements, or end arrangements that the Company does not believe are beneficial; the uncertainties as to the impact of the non-renewal of our agreement with Sanofi; operating an international business; uncertainty in the prospects for unapproved products, including ProFlow and Neucardin®, including uncertainties as to pricing and competition and risks relating to the clinical trial process and related regulatory approval process and the process of initiating trials at, and enrolling patients at, clinical sites; and the effect of changes in its practices and policies related to the Company's compliance programs. SciClone cannot predict the timing or outcome of the ongoing SEC and DOJ investigations, or of the level of its efforts required to cooperate with those investigations, however, the Company has incurred substantial expenses in connection with the investigations and related litigation and expects to incur substantial additional expense, and the investigations could result in fines that exceed the minimum amount accrued and further changes in its internal control or other remediation measures that could adversely affect its financial results. Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.
SCICLONE PHARMACEUTICALS, INC. UNAUDITED CONSOLIDATED STATEMENTS OF INCOME (in thousands, except per share amounts) Three Months Ended Year Ended December 31, December 31, -------------------- -------------------- 2013 2012 2013 2012 --------- --------- --------- --------- Net revenues: Product sales, net $ 31,925 $ 24,587 $ 99,414 $ 123,171 Promotion services 809 8,552 27,644 33,098 --------- --------- --------- --------- Total net revenues 32,734 33,139 127,058 156,269 Operating expenses: Cost of product sales 6,037 5,326 17,668 21,996 Sales and marketing 13,855 18,120 55,821 70,327 Amortization of acquired intangible assets, related to sales and marketing - - - 2,645 Research and development 1,142 393 7,463 5,145 General and administrative 7,704 7,353 32,496 21,344 Restructuring charges 1,181 - 1,181 1,096 Estimated SEC and DOJ investigation loss 2,000 - 2,000 - Intangible asset impairment - - - 42,728 Change in fair value of contingent consideration - (562) - (15,422) --------- --------- --------- --------- Total operating expenses 31,919 30,630 116,629 149,859 --------- --------- --------- --------- Income from operations 815 2,509 10,429 6,410 Non-operating income (expense): Interest income 24 16 85 89 Interest expense (9) (18) (103) (185) Other income (expense), net 20 (20) 2,795 (42) --------- --------- --------- --------- Income before provision (benefit) for income tax 850 2,487 13,206 6,272 Provision (benefit) for income tax 814 599 2,242 (3,348) --------- --------- --------- --------- Net income $ 36 $ 1,888 $ 10,964 $ 9,620 ========= ========= ========= ========= Basic net income per share $ 0.00 $ 0.03 $ 0.20 $ 0.17 Diluted net income per share $ 0.00 $ 0.03 $ 0.20 $ 0.16 Weighted average shares used in computing: Basic net income per share 52,567 55,007 53,587 56,637 Diluted net income per share 53,785 56,471 54,936 58,483 SCICLONE PHARMACEUTICALS, INC. RECONCILIATION OF GAAP TO NON-GAAP NET INCOME (in thousands, except per share amounts) (unaudited) Three Months Ended Year Ended December 31, December 31, ------------------- ------------------- 2013 2012 2013 2012 --------- --------- --------- --------- GAAP net income $ 36 $ 1,888 $ 10,964 $ 9,620 Non-GAAP adjustments: Employee stock-based compensation 799 709 4,007 3,897 In-license upfront costs - - 5,000 - Restructuring charges 1,181 - 1,181 1,096 Estimated SEC and DOJ investigation loss 2,000 - 2,000 - Amortization of acquired intangible assets - - - 2,645 Intangible asset impairment - - - 42,728 Change in fair value of contingent consideration - (562) - (15,422) Net tax benefit related to NovaMed deferred tax assets and liabilities - - - (6,800) --------- --------- --------- --------- Non-GAAP net income $ 4,016 $ 2,035 $ 23,152 $ 37,764 ========= ========= ========= ========= Non-GAAP basic net income per share $ 0.08 $ 0.04 $ 0.43 $ 0.67 Non-GAAP diluted net income per share $ 0.07 $ 0.04 $ 0.42 $ 0.65 Weighted average shares used in computing: Non-GAAP basic net income per share 52,567 55,007 53,587 56,637 Non-GAAP diluted net income per share 53,785 56,471 54,936 58,483
SciClone management uses these non-GAAP financial measures to monitor and evaluate the Company's operating results and trends on an on-going basis and internally for operations, budgeting and financial planning purposes. SciClone believes the non-GAAP information is useful for investors by offering them the ability to better understand how management evaluates the business. These non-GAAP measures have limitations, however, because they do not include all items of income and expenses that affect SciClone. These non-GAAP financial measures that management uses are not prepared in accordance with, and should not be considered in isolation of, or as an alternative to, measurements required by GAAP.
SciClone's non-GAAP financial measures exclude the following items from GAAP net income and net income per share:
SCICLONE PHARMACEUTICALS, INC. UNAUDITED SELECTED BALANCE SHEET DATA (in thousands) December 31, December 31, 2013 2012 ------------- ------------- Cash, cash equivalents, and investments $ 85,878 $ 86,987 Accounts receivable 40,008 38,109 Inventories 15,238 10,424 Goodwill 35,357 34,313 Total assets 180,227 174,071 Total current liabilities 33,588 30,812 Deferred tax liabilities 368 153 Short-term borrowings 1,651 1,445 Total shareholders' equity 146,595 143,022